Renal and metabolic effects of L-arginine infusion in kidney transplant recipients.
OBJECTIVE
In order to investigate the role of kidney damage on renal response to L-arginine (L-Arg) infusion in transplant patients receiving cyclosporine A (CsA) treatment, we assessed systemic and glomerular hemodynamic variables, the fraction excretion of urinary sodium, albumin, cyclic GMP (as an index of nitric oxide (NO) production from L-Arg) and urea excretion (as an index of ureagenesis), and glucoregulatory hormone levels in five normal volunteers and 21 renal allograft recipients (aged 10-20 years) treated with CsA, 10 with normal renal function and 11 with chronic renal insufficiency.


RESULTS
In the normal subjects, L-Arg infusion (290 mg/min/1.73 m2 for 1 h) significantly reduced mean arterial pressure (MAP) (76+/-7 to 70+/-5 mmHg) and renal vascular resistance (RVR), and increased GFR (103+/-9 to 122+/-7 min/1.73 m2), RPF, urinary cyclic GMP excretion (0.40+/-0.1 to 0.60+/-0.1 nmol/100 ml glomerular filtrate (GF)), and sodium and albumin excretion. Neither the patients with chronic graft dysfunction nor those with a normal graft responded to L-Arg infusion: RVR remained high, and MAP, GFR, RPF, fractional excretion of sodium and urinary excretion of albumin and cyclic GMP were unchanged in both groups of patients. Glucagon, insulin and urinary urea excretion rose significantly in controls and both patient groups.


CONCLUSIONS
The hemodynamic effects of L-Arg infusion were inhibited in the patients, regardless of their degree of renal function, possibly because L-Arg-NO production was blunted.
Zhang
X Z
XZ
Clinica Pediatrica II, Università di Milano, Milan, Italy.
Ghio
L
L
Ardissino
G
G
Tirelli
A S
AS
Daccò
V
V
Testa
S
S
Claris-Appiani
A
A
D000293:Adolescent; D000328:Adult; D001120:Arginine / Q000008:administration & dosage / Q000494:pharmacology*; D002648:Child; D006152:Cyclic GMP / Q000096:biosynthesis; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006084:Graft Rejection / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007262:Infusions, Intravenous; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D012016:Reference Values; D012964:Sodium / Q000652:urine; D014655:Vascular Resistance / Q000187:drug effects; D010130:p-Aminohippuric Acid / Q000652:urine
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001120:Arginine; D012964:Sodium; D006152:Cyclic GMP; D010130:p-Aminohippuric Acid